![]() Ranbaxy receives approval to mkt Cefprozil tablets, powderPublished on Thu, Apr 12, 2007 at 14:51 | Source : Moneycontrol.com Updated at Thu, Apr 12, 2007 at 16:57
Ranbaxy Laboratories Limited (RLL), announced today that the Company has received approval to manufacture and market RAN™-Cefprozil Tablets, 250mg and 500mg, and RAN™-Cefprozil Powder for Oral Suspension, 250mg/5mL from Health Cefprozil Tablets and Powder for Oral Suspension are indicated for the treatment of upper respiratory tract infections, uncomplicated skin and urinary tract infections. "We are pleased to receive these approvals for RAN™-Cefprozil, Tablets and Powder for Oral Suspension to expand the number of product offerings that Ranbaxy commercializes for use by patients who require the therapeutic benefits of this product where indicated. This further adds to our expanding generic product portfolio which will have benefits of offering an affordable generic alternative to the brand that will now be accessible to all Canadians," according to Bill Abboud, President, RPCI. Ranbaxy Pharmaceuticals Canada Inc ., (RPCI) based in
Sourced From: Ranbaxy Laboratories Ltd
PREVIOUS STORY Trending NewsBusiness News
|
NewsVideos
Interviews
May 27 2012, 11:52 | Source: CNBC-TV18 ![]() May 27 2012, 11:00 | Source: CNBC-TV18 ![]() Subscribe to Moneycontrol Newsletters |
|||||||